- Home
- COCH vs TENX Comparison
COCH vs TENX Comparison
Compare COCH & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | TENX |
|---|---|---|
| Founded | 1995 | 1967 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.7M | 56.2M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | COCH | TENX |
|---|---|---|
| Price | $0.69 | $15.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.00 | ★ $29.67 |
| AVG Volume (30 Days) | 320.4K | ★ 411.7K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $4.64 |
| 52 Week High | $1.91 | $18.38 |
Technical Indicators
Market Signals| Indicator | COCH | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 61.59 |
| Support Level | $0.65 | $12.71 |
| Resistance Level | $0.73 | $16.27 |
| Average True Range (ATR) | 0.09 | 1.30 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 23.45 | 73.73 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.